| Prev Close | 16.96 |
| Open | 16.96 |
| Day Low/High | 16.96 / 16.98 |
| 52 Wk Low/High | 3.02 / 17.05 |
| Volume | 8.44M |
| Avg Volume | 6.29M |
| Exchange | NASDAQ |
| Shares Outstanding | 193.76M |
| Market Cap | 3.29B |
| EPS | -0.31 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Avanir Pharmaceuticals Announces FDA Approval Of ONZETRA™ Xsail™ (AVP-825) For The Acute Treatment Of Migraine In Adults
--ONZETRA Xsail is the first breath-powered intranasal medication delivery system for the acute treatment of migraine--
Avanir Pharmaceuticals Announces Publication Of Study Evaluating The Prevalence Of Pseudobulbar Affect (PBA) Symptoms And Use Of Antipsychotic Medications In Nursing Homes
-- First Study to Evaluate the Prevalence of PBA Symptoms in Nursing Home Residents Found Almost 1 in 10 Residents Had Symptoms of PBA; These Patients with PBA Symptoms were Twice as Likely to Receive Antipsychotics --
Avanir Pharmaceuticals Announces Initiation Of Phase III Trial Of AVP-786 For Agitation In Patients With Alzheimer's Disease
-- AVP-786 Granted FDA Fast Track Designation for This Indication --
Avanir Pharmaceuticals Announces New Findings From Dementia/Alzheimer's Disease Cohort Of PRISM II Study At Alzheimer's Association International Conference
--New Data Demonstrate Treatment Effects on Pseudobulbar Affect (PBA) with NUEDEXTA Regardless of Concomitant Antidepressant Use--
Avanir Pharmaceuticals Announces Positive Top-line Results From Stroke And TBI Cohorts Of PRISM II Study
-- Results Show NUEDEXTA Provides Meaningful Reduction of PBA Episodes and is Generally Well Tolerated in PBA Patients Who Had an Underlying Stroke or Traumatic Brain Injury --
Avanir Pharmaceuticals Announces Presentation Of Survey Evaluating The Prevalence Of Pseudobulbar Affect (PBA) Symptoms In Retired Professional Football Players At The 12th Annual North American Brain Injury Society Conference
-- Ninety nine percent of respondents experienced some form of brain trauma during their playing career and one third also report symptoms of PBA --
Danny Glover Joins PBA Facts Campaign, To Educate And Build Awareness Of Pseudobulbar Affect (PBA), A Little Known But Widespread Neurologic Condition
--Avanir Pharmaceuticals Takes Unique Approach to Patient Education in New Initiative--
Football Hall-of-Famer Barry Sanders Tackles Pseudobulbar Affect; A Little-known But Widespread Condition Caused By Brain Injury
'Tackle PBA,' a New Educational Campaign, Addresses Why Many Former Pro Football Players Cry or Laugh Uncontrollably with Little to No Clear Trigger
Through Laughter And Tears Comes First-Ever Documentary About Life With PseudoBulbar Affect (PBA)
--Award-Winning Filmmakers Capture Untold Story of Little-Known Neurologic Condition That Affects Nearly 2 Million Americans--
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Avanir Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of...
AVANIR PHARMACEUTICALS SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Avanir Pharmaceuticals, Inc. Over The Proposed Sale Of The Company To Otsuka Pharmaceutical Co., Ltd. - AVNR
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Avanir Pharmaceuticals, Inc.
Jim Cramer on the Stock Market: You Have to Love Biotech
In this era of turmoil, investors can take comfort in this sector.
